Scholarlink

<p>In 26 patients with chronic obstructive pulmonary disease (COPD), validation of the marker genes <i>RARB</i>, <i>ZNF260</i>, and <i>DCDC1</i> was carried out using liquid biopsy technology. Hypermethylation of <i>RARB</i>, <i>ZNF260</i>, and <i>DCDC1</i> genes in extracellular DNA of the blood plasma was revealed. Post-therapeutic monitoring showed that hypermethylation of the <i>RARB</i> and/or <i>ZNF260</i> genes was associated with the development of lung cancer in 23% of cases. These findings show the potential of analyzing the epigenetic markers for assessing the risk of lung cancer development in COPD patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating DNA-Markers of High Risk for Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease

  • 期刊论文

  • 发表日期：

    2026年6月2日

查看全文
  • A. A. Ponomaryova,
  • V. V. Boyarko,
  • L. Wang,
  • Z. Huang,
  • A. A. Korobeynikova,
  • P. A. Gervas,
  • D. V. Kapitanova,
  • E. B. Bukreeva,
  • O. V. Pancova,
  • A. A. Zarubin,
  • V. M. Perelmuter,
  • N. V. Cherdyntseva,
  • E. V. Denisov

摘要

In 26 patients with chronic obstructive pulmonary disease (COPD), validation of the marker genes RARB, ZNF260, and DCDC1 was carried out using liquid biopsy technology. Hypermethylation of RARB, ZNF260, and DCDC1 genes in extracellular DNA of the blood plasma was revealed. Post-therapeutic monitoring showed that hypermethylation of the RARB and/or ZNF260 genes was associated with the development of lung cancer in 23% of cases. These findings show the potential of analyzing the epigenetic markers for assessing the risk of lung cancer development in COPD patients.